Jifeng Feng

1.3k total citations · 1 hit paper
27 papers, 895 citations indexed

About

Jifeng Feng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jifeng Feng has authored 27 papers receiving a total of 895 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Jifeng Feng's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Electric and Hybrid Vehicle Technologies (3 papers). Jifeng Feng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Electric and Hybrid Vehicle Technologies (3 papers). Jifeng Feng collaborates with scholars based in China, United States and Hong Kong. Jifeng Feng's co-authors include Jianjun Zou, Shusen Wang, Quchang Ouyang, Wěi Li, Huiping Li, Shiying Yu, Zhongsheng Tong, Zefei Jiang, Fei Ma and Yunjiang Liu and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and Blood.

In The Last Decade

Jifeng Feng

26 papers receiving 876 citations

Hit Papers

Nivolumab Versus Docetaxel in a Predominantly Chinese Pat... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
    2019 265 citations Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jifeng Feng China 12 526 356 206 148 114 27 895
Yunpeng Liu China 20 501 1.0× 454 1.3× 522 2.5× 354 2.4× 179 1.6× 78 1.3k
Fiona Chionh Australia 15 393 0.7× 152 0.4× 344 1.7× 142 1.0× 95 0.8× 26 839
Yonggao Mou China 17 265 0.5× 216 0.6× 294 1.4× 216 1.5× 194 1.7× 60 892
Łukasz Szylberg Poland 17 367 0.7× 163 0.5× 314 1.5× 211 1.4× 115 1.0× 81 923
Lin Zhong China 15 341 0.6× 217 0.6× 235 1.1× 129 0.9× 149 1.3× 59 1.0k
Wei Bai China 13 363 0.7× 191 0.5× 397 1.9× 216 1.5× 83 0.7× 54 911
Tomoyuki Aoyama Japan 14 229 0.4× 306 0.9× 188 0.9× 110 0.7× 27 0.2× 38 652
G. Hu China 14 334 0.6× 115 0.3× 274 1.3× 181 1.2× 62 0.5× 33 672
Marva Maya United States 7 236 0.4× 230 0.6× 225 1.1× 99 0.7× 87 0.8× 8 564

Countries citing papers authored by Jifeng Feng

Since Specialization
Citations

This map shows the geographic impact of Jifeng Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jifeng Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jifeng Feng more than expected).

Fields of papers citing papers by Jifeng Feng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jifeng Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jifeng Feng. The network helps show where Jifeng Feng may publish in the future.

Co-authorship network of co-authors of Jifeng Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Jifeng Feng. A scholar is included among the top collaborators of Jifeng Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jifeng Feng. Jifeng Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Zhisong, Mingjun Zhang, Shusuan Jiang, et al.. (2024). BGB-A317-212: A multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2610–2610. 1 indexed citations
2.
Zou, Dan, Bowen Hu, Yan Lv, et al.. (2024). Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma. Cell & Bioscience. 14(1). 143–143.
3.
Du, Xiaoyue, Cong Xu, Jiang Feng, et al.. (2024). Identification of macrophage-related genes correlated with prognosis and immunotherapy efficacy in non-small cell lung cancer. Heliyon. 10(6). e27170–e27170. 2 indexed citations
4.
Ren, Shengxiang, Jifeng Feng, Shenglin Ma, et al.. (2023). KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer. 153(3). 623–634. 12 indexed citations
5.
Ning, Zhipeng, et al.. (2022). Association between perinatal pain and postpartum depression: A systematic review and meta-analysis. Journal of Affective Disorders. 312. 92–99. 22 indexed citations
6.
7.
Feng, Jifeng, et al.. (2019). Research on Power Allocation Control Strategy For Compound Electric Energy Storage System of Pure Electric Bus. Diangong Jishu Xuebao. 34(23). 5001–5013. 3 indexed citations
8.
Hu, Xiao, et al.. (2019). miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5. Current Molecular Pharmacology. 13(2). 144–149. 20 indexed citations
9.
Ma, Fei, Quchang Ouyang, Wěi Li, et al.. (2019). Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Journal of Clinical Oncology. 37(29). 2610–2619. 247 indexed citations
10.
Wu, Yi‐Long, Shun Lü, Ying Cheng, et al.. (2019). Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology. 14(5). 867–875. 265 indexed citations breakdown →
11.
Yu, Zhongwang, Weili Liu, Dou Yin, et al.. (2018). Plasma Hemopexin ameliorates murine spinal cord injury by switching microglia from the M1 state to the M2 state. Cell Death and Disease. 9(2). 41 indexed citations
12.
Chen, Yu, et al.. (2018). Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p. Biomedicine & Pharmacotherapy. 109. 2327–2334. 44 indexed citations
13.
Feng, Jifeng, et al.. (2018). Research on the energy management of composite energy storage system in electric vehicles. International Journal of Electric and Hybrid Vehicles. 10(1). 41–41. 1 indexed citations
14.
15.
Yu, Shaorong, et al.. (2017). MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anti-Cancer Drugs. 28(8). 852–860. 41 indexed citations
16.
Chen, Baoan, Ke Li, Guohua Xia, et al.. (2013). Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. International Journal of Nanomedicine. 8. 1867–1867. 38 indexed citations
17.
Xu, Peipei, Baoan Chen, Jifeng Feng, et al.. (2012). Polymorphisms in XPC provide prognostic information in acute myeloid leukemia. International Journal of Hematology. 96(4). 450–460. 11 indexed citations
18.
Zhong, Yuejiao, Baoan Chen, Jifeng Feng, et al.. (2010). The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leukemia & lymphoma. 51(6). 1115–1120. 11 indexed citations
19.
Shi, Meiqi, Chang‐Ming Gao, Jian Wu, et al.. (2006). [Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer].. PubMed. 9(6). 519–24. 5 indexed citations
20.
Feng, Jifeng. (2005). Polymorphism in the 3′-untranslated region of thymidylate synthase gene and sensitivity of stomach cancer to fluoropymidine-based chemotherapy. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yunpeng Liu Breakdown of academic impact, for papers by Fiona Chionh Breakdown of academic impact, for papers by Yonggao Mou Breakdown of academic impact, for papers by Łukasz Szylberg Breakdown of academic impact, for papers by Lin Zhong Breakdown of academic impact, for papers by Wei Bai Breakdown of academic impact, for papers by Tomoyuki Aoyama Breakdown of academic impact, for papers by G. Hu Breakdown of academic impact, for papers by Marva Maya
Rankless by CCL
2026